Cabozantinib Resolves Bone Scans in Tumor-Naïve Mice Harboring Skeletal Injuries
The receptor tyrosine kinase inhibitor cabozantinib (XL184, BMS-907351 Cometriq) has displayed impressive clinical activity against several indications, culminating in its recent approval for medullary thyroid cancer. Among malignancies with tropism for the bone (prostate, breast), one striking feat...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi - SAGE Publishing
2014-10-01
|
| Series: | Molecular Imaging |
| Online Access: | https://doi.org/10.2310/7290.2014.00026 |